B cells and their cytokine activities implications in human diseases
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
B cells are the only cell type that can give rise to antibody-producing cells, and the only cell type whose selective depletion can, today, lead to an improvement of a wide range of immune-mediated inflammatory diseases, including disorders not primarily driven by autoantibodies. Here, I discuss this paradoxical observation, and propose that the capacity of B cells to act as cytokine-producing cells explains how they can control monocyte activity and subsequently disease pathogenesis. Together with current data on the effect of anti-CD20 B cell-depleting reagents in the clinic, this novel knowledge on B cell heterogeneity opens the way for novel safer and more efficient strategies to target B cells. The forthcoming identification of disease-relevant B cell subsets is awaited to permit their monitoring and specific targeting in a personalized medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
B cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
Self-citationImmunopathogenesis of Rheumatoid Arthritis
Firestein, G. S., & McInnes, I. B. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.006 · Cited by 1,301
Shen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048
Self-citationAntibody-independent functions of B cells: a focus on cytokines
Shen, P., & Fillatreau, S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3857 · Cited by 508
Self-citationTLR-Activated B Cells Suppress T Cell-Mediated Autoimmunity
Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Gómez, E. C., Sweenie, C. H., Hao, Y., Freitas, A. A., Steinhoff, U., Anderton, S. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4763 · Cited by 436
Self-citationAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Research works printed but not linked: 92
- Cunningham-Rundles, 2005, Molecular defects in T- and B-cell primary immunodeficiency diseases, Nat. Rev. Immunol., 5, 880, 10.1038/nri1713 · DOI · Paper page
- Gelfand, 2017, Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis, Neurotherapeutics, 10.1007/s13311-017-0557-4 · DOI · Paper page
- Link, 1977, Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis, Scand. J. Clin. Lab. Invest., 37, 397, 10.3109/00365517709091498 · DOI
- Fillatreau, 2007, B-cell function in CNS inflammatory demyelinating disease: a complexity of roles and a wealth of possibilities, Expert. Rev. Clin. Immunol., 3, 565, 10.1586/1744666X.3.4.565 · DOI
- Brandle, 2016, Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins, Proc. Natl. Acad. Sci. U. S. A., 113, 7864, 10.1073/pnas.1522730113 · DOI · Paper page
- Vermeulen, 2011, Identification of a novel autoantigen in inflammatory bowel disease by protein microarray, Inflamm. Bowel Dis., 17, 1291, 10.1002/ibd.21508 · DOI
- von Budingen, 2008, Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies, Eur. J. Immunol., 38, 2014, 10.1002/eji.200737784 · DOI · Paper page
- Ritchie, 2004, Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis, J. Immunol., 173, 649, 10.4049/jimmunol.173.1.649 · DOI
- Storch, 1998, Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination, Ann. Neurol., 43, 465, 10.1002/ana.410430409 · DOI · Paper page
- Genain, 1999, Identification of autoantibodies associated with myelin damage in multiple sclerosis, Nat. Med., 5, 170, 10.1038/5532 · DOI · Paper page
- Schluesener, 1987, A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease, J. Immunol., 139, 4016, 10.4049/jimmunol.139.12.4016 · DOI · Paper page
- Lalive, 2006, Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis, Proc. Natl. Acad. Sci. U. S. A., 103, 2280, 10.1073/pnas.0510672103 · DOI · Paper page
- Kappos, 2011, Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, Lancet, 378, 1779, 10.1016/S0140-6736(11)61649-8 · DOI · Paper page
- Petereit, 2008, Rituximab in a patient with multiple sclerosis—effect on B cells, plasma cells and intrathecal IgG synthesis, Acta Neurol. Scand., 117, 399, 10.1111/j.1600-0404.2007.00958.x · DOI
- Barr, 2012, B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells, J. Exp. Med., 209, 1001, 10.1084/jem.20111675 · DOI · Paper page
- Molnarfi, 2013, MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies, J. Exp. Med., 210, 2921, 10.1084/jem.20130699 · DOI · Paper page
- Bar-Or, 2010, Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?, Ann. Neurol., 67, 452, 10.1002/ana.21939 · DOI · Paper page
- Miyazaki, 2014, A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected], PLoS One, 9, e105421, 10.1371/journal.pone.0105421 · DOI
- Li, 2015, Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy, Sci. Transl. Med., 7, 310ra166, 10.1126/scitranslmed.aab4176 · DOI · Paper page
- Ngo, 1999, Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen, J. Exp. Med., 189, 403, 10.1084/jem.189.2.403 · DOI · Paper page
- Krumbholz, 2006, Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment, Brain, 129, 200, 10.1093/brain/awh680 · DOI · Paper page
- Piccio, 2010, Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis, Arch. Neurol., 67, 707, 10.1001/archneurol.2010.99 · DOI · Paper page
- Cross, 2006, Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients, J. Neuroimmunol., 180, 63, 10.1016/j.jneuroim.2006.06.029 · DOI · Paper page
- El Behi, 2017, Adaptive human immunity drives remyelination in a mouse model of demyelination, Brain, 140, 967, 10.1093/brain/awx008 · DOI
- Lino, 2016, Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases, Immunol. Rev., 269, 130, 10.1111/imr.12374 · DOI · Paper page
- Yoshizaki, 2012, Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions, Nature, 491, 264, 10.1038/nature11501 · DOI · Paper page
- Duddy, 2007, Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis, J. Immunol., 178, 6092, 10.4049/jimmunol.178.10.6092 · DOI · Paper page
- Iwata, 2011, Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells, Blood, 117, 530, 10.1182/blood-2010-07-294249 · DOI · Paper page
- Heine, 2014, Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts, Eur. J. Immunol., 44, 1615, 10.1002/eji.201343822 · DOI
- Larousserie, 2006, Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas, J. Pathol., 209, 360, 10.1002/path.1995 · DOI
- de Masson, 2015, CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease, Blood, 125, 1830, 10.1182/blood-2014-09-599159 · DOI · Paper page
- Hartung, 2010, Atacicept: targeting B cells in multiple sclerosis, Ther. Adv. Neurol. Disord., 3, 205, 10.1177/1756285610371146 · DOI
- Correale, 2008, Helminth infections associated with multiple sclerosis induce regulatory B cells, Ann. Neurol., 64, 187, 10.1002/ana.21438 · DOI · Paper page
- Correale, 2007, Association between parasite infection and immune responses in multiple sclerosis, Ann. Neurol., 61, 97, 10.1002/ana.21067 · DOI · Paper page
- Carter, 2010, Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis, Drugs, 70, 1545, 10.2165/11204560-000000000-00000 · DOI
- Ireland, 2014, The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis, JAMA Neurol., 71, 1421, 10.1001/jamaneurol.2014.1472 · DOI
- Kala, 2010, B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis, Exp. Neurol., 221, 136, 10.1016/j.expneurol.2009.10.015 · DOI
- Miyazaki, 2014, Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations, Clin. Immunol., 151, 127, 10.1016/j.clim.2014.02.001 · DOI
- Grutzke, 2015, Fingolimod treatment promotes regulatory phenotype and function of B cells, Ann. Clin. Transl. Neurol., 2, 119, 10.1002/acn3.155 · DOI
- McInnes, 2017, Pathogenetic insights from the treatment of rheumatoid arthritis, Lancet, 389, 2328, 10.1016/S0140-6736(17)31472-1 · DOI · Paper page
- Brink, 2013, Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis, Arthritis Rheum., 65, 899, 10.1002/art.37835 · DOI · Paper page
- Rantapaa-Dahlqvist, 2003, Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis, Arthritis Rheum., 48, 2741, 10.1002/art.11223 · DOI · Paper page
- Iwaki-Egawa, 2005, Production of anti-CCP antibodies and matrix metalloproteinase-3 by human rheumatoid arthritis synovial tissues using SCID mice, Ann. Rheum. Dis., 64, 1094, 10.1136/ard.2004.032847 · DOI
- Vos, 2007, Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis, Arthritis Rheum., 56, 772, 10.1002/art.22400 · DOI · Paper page
- Doorenspleet, 2014, Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity, Ann. Rheum. Dis., 73, 756, 10.1136/annrheumdis-2012-202861 · DOI
- Silverman, 2003, Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy, Arthritis Rheum., 48, 1484, 10.1002/art.10947 · DOI · Paper page
- Keystone, 2009, Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies, Ann. Rheum. Dis., 68, 216, 10.1136/ard.2007.085787 · DOI · Paper page
- Wheater, 2011, Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis, Osteoporos. Int., 22, 3067, 10.1007/s00198-011-1607-0 · DOI
- Boumans, 2012, Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis, Ann. Rheum. Dis., 71, 108, 10.1136/annrheumdis-2011-200198 · DOI
- Rosengren, 2011, CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis, Rheumatology (Oxford), 50, 603, 10.1093/rheumatology/keq337 · DOI
- Sellam, 2013, CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis, Arthritis Rheum., 65, 2253, 10.1002/art.38023 · DOI
- Hogan, 2012, Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab, Ann. Rheum. Dis., 71, 1888, 10.1136/annrheumdis-2011-201115 · doi:10.1136/annrheumdis-2011-201115
- Isaacs, 2013, Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis, Ann. Rheum. Dis., 72, 329, 10.1136/annrheumdis-2011-201117 · DOI · Paper page
- Emery, 2006, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis Rheum., 54, 1390, 10.1002/art.21778 · DOI · Paper page
- Emery, 2011, Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response, Ann. Rheum. Dis., 70, 2063, 10.1136/ard.2010.148015 · DOI
- Kuhn, 2006, Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis, J. Clin. Invest., 116, 961, 10.1172/JCI25422 · DOI · Paper page
- Cambridge, 2003, Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis, Arthritis Rheum., 48, 2146, 10.1002/art.11181 · DOI · Paper page
- Tak, 2008, Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study, Arthritis Rheum., 58, 61, 10.1002/art.23178 · DOI · Paper page
- van Vollenhoven, 2011, Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial, Arthritis Rheum., 63, 1782, 10.1002/art.30372 · DOI · Paper page
- Lal, 2011, Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment, Arthritis Rheum., 63, 3681, 10.1002/art.30596 · DOI
- Cambridge, 2014, The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment, J. Autoimmun., 50, 67, 10.1016/j.jaut.2013.12.002 · DOI
- Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. U. S. A., 95, 3597, 10.1073/pnas.95.7.3597 · DOI · Paper page
- Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X · DOI · Paper page
- Chiu, 2017, Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis, Expert. Opin. Biol. Ther., 17, 119, 10.1080/14712598.2017.1263614 · DOI
- Meednu, 2016, Production of RANKL by memory B cells: a link between B cells and bone erosion in rheumatoid arthritis, Arthritis Rheum., 68, 805, 10.1002/art.39489 · DOI · Paper page
- Onal, 2012, Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss, J. Biol. Chem., 287, 29851, 10.1074/jbc.M112.377945 · DOI · Paper page
- Ota, 2016, Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis, Arthritis Res. Ther., 18, 67, 10.1186/s13075-016-0957-6 · DOI
- James, 2014, Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy, Arthritis Rheum., 66, 1712, 10.1002/art.38637 · DOI · Paper page
- Yamada, 2008, Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis, Ann. Rheum. Dis., 67, 1299, 10.1136/ard.2007.080341 · DOI · Paper page
- Yellin, 2012, A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis, Arthritis Rheum., 64, 1730, 10.1002/art.34330 · DOI · Paper page
- Banko, 2017, Induction and differentiation of IL-10-producing regulatory B cells from healthy blood donors and rheumatoid arthritis patients, J. Immunol., 198, 1512, 10.4049/jimmunol.1600218 · DOI
- Wilson, 2012, Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG, J. Immunol., 188, 4741, 10.4049/jimmunol.1102651 · DOI
- Yeo, 2015, Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis, Ann. Rheum. Dis., 74, 928, 10.1136/annrheumdis-2013-204116 · DOI
- Amara, 2017, B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis, J. Autoimmun., 81, 34, 10.1016/j.jaut.2017.03.004 · DOI
- Ehrhardt, 2005, Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells, J. Exp. Med., 202, 783, 10.1084/jem.20050879 · DOI · Paper page
- Olalekan, 2015, B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis, Eur. J. Immunol., 45, 988, 10.1002/eji.201445036 · DOI · Paper page
- Hamel, 2014, B cell-specific expression of inducible costimulator ligand is necessary for the induction of arthritis in mice, Arthritis Rheum., 66, 60, 10.1002/art.38207 · DOI
- Crotty, 2011, Follicular helper CD4 T cells (TFH), Annu. Rev. Immunol., 29, 621, 10.1146/annurev-immunol-031210-101400 · DOI · Paper page
- O'Neill, 2007, Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis, J. Immunol., 179, 5109, 10.4049/jimmunol.179.8.5109 · DOI
- Lee, 2012, Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers, Immunity, 37, 880, 10.1016/j.immuni.2012.10.010 · DOI · Paper page
- Carter, 2012, Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis, Arthritis Res. Ther., 14, R32, 10.1186/ar3736 · DOI · Paper page
- Carter, 2011, Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells, J. Immunol., 186, 5569, 10.4049/jimmunol.1100284 · DOI · Paper page
- Daien, 2014, Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity, Arthritis Rheum., 66, 2037, 10.1002/art.38666 · DOI · Paper page
- Liu, 2014, TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells, Eur. J. Immunol., 44, 2121, 10.1002/eji.201344341 · DOI
- Ettinger, 2005, IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells, J. Immunol., 175, 7867, 10.4049/jimmunol.175.12.7867 · DOI · Paper page
- Rasmussen, 2016, Helper cells and IL-21 in rheumatic diseases, Dan Med. J., 63
- Fillatreau, 2015, Regulatory plasma cells, Curr. Opin. Pharmacol., 23, 1, 10.1016/j.coph.2015.04.006 · DOI
- Ries, 2014, B-type suppression: a role played by “regulatory B cells” or “regulatory plasma cells”, Eur. J. Immunol., 44, 1251, 10.1002/eji.201343683 · DOI
- Leandro, 2013, B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies, Arthritis Res. Ther., 15, S3, 10.1186/ar3908 · DOI · Paper page
- Kamburova, 2013, A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function, Am. J. Transplant., 13, 1503, 10.1111/ajt.12220 · DOI · Paper page
- Vancsa, 2013, Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion, J. Rheumatol., 40, 565, 10.3899/jrheum.111488 · doi:10.3899/jrheum.111488
- Tak, 2012, Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial, Arthritis Rheum., 64, 360, 10.1002/art.33353 · DOI
Cited by
Gut-microbiota-targeted diets modulate human immune status
Wastyk, H. C., Fragiadakis, G. K., Perelman, D., Dahan, D., Merrill, B. D., Yu, F. B., Topf, M., Gonzalez, C. G., Van Treuren, W., Han, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.019 · Cited by 1,385
Interferon-γ: teammate or opponent in the tumour microenvironment?
Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00566-3 · Cited by 582
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Metadata
- Authors
- Fillatreau, S.
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 186
- Pages
- 26-31
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W2738499080
- Cited by
- 68
- References
- 10
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- European Research Council (647696)
- Agence Nationale de la recherche (ANR-16-CE18-0007-01)
- ABIR (031A403)
- Deutsche Forschungsgemeinschaft (TRR130, FI 1238/1-2)
- Bundesministerium für Bildung und Forschung (BMBF Neu2 16GW0069)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B cells and their cytokine activities implications in human diseases. https://app.cochat.ai/papers/10.1016/j.clim.2017.07.020
- The paper
- Fillatreau, S. (2018). B cells and their cytokine activities implications in human diseases. Clinical Immunology. https://doi.org/10.1016/j.clim.2017.07.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.